Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 30

Results For "zydus"

376 News Found

Zydus Cadila’s Sitagliptin base tablets receive tentative approval from US FDA
Drug Approval | September 06, 2021

Zydus Cadila’s Sitagliptin base tablets receive tentative approval from US FDA

Zydus’ Sitagliptin base contains the active moiety Sitagliptin in a different form than used in the branded reference product, Januvia (Sitagliptin Phosphate)


Zydus gets USFDA approval for arthritis drug
News | August 23, 2021

Zydus gets USFDA approval for arthritis drug

Zydus was the first to file an ANDA for Tofacitinib extended-release tablets 22 mg and currently holds 180-day exclusivity on this strength


Zydus ties up with CHEMI to launch Enoxaparin Sodium injection in the US
Drug Approval | August 20, 2021

Zydus ties up with CHEMI to launch Enoxaparin Sodium injection in the US

Enoxaparin Sodium Injection, USP is used for prophylaxis of Deep Vein Thrombosis (DVT) in patients undergoing abdominal, hip or knee replacement surgery, and also for the treatment of acute DVT


Zydus Cadila receives Emergency Use Authorisation for 3-dose ZyCoV-D vaccine
Biotech | August 20, 2021

Zydus Cadila receives Emergency Use Authorisation for 3-dose ZyCoV-D vaccine

This is the world’s first Covid=19 DNA vaccine developed in partnership with DBT-BIRAC


Zydus Cadila receives tentative approval for cancer drug
News | August 17, 2021

Zydus Cadila receives tentative approval for cancer drug

Lenalidomide is used to treat cancer and also some anaemia disorders


Zydus Cadila receives final approval for Mesalamine extended-release capsules
Drug Approval | August 16, 2021

Zydus Cadila receives final approval for Mesalamine extended-release capsules

The group has a total of 320 ANDA approvals


Zydus Cadila receives approval from USFDA for Fulvestrant Injection
News | July 31, 2021

Zydus Cadila receives approval from USFDA for Fulvestrant Injection

The group now has 320 approvals and has so far filed over 400 ANDAs


Zydus Wellness Q1FY22 consolidated net profit at Rs. 130.80 Cr
News | July 31, 2021

Zydus Wellness Q1FY22 consolidated net profit at Rs. 130.80 Cr

The company posted net profit of Rs.89.20 crores for the period ended June 30, 2020.


Zydus Cadila receives USFDA approval for Emtricitabine and Tenofovir Disoproxil
News | July 04, 2021

Zydus Cadila receives USFDA approval for Emtricitabine and Tenofovir Disoproxil

The drug is used with other HIV medications to help control HIV infection and it helps to decrease the amount of HIV in one’s body so that the immune system can work better


Zydus applies to the DCGI for EUA to launch ZyCoV-D
News | July 01, 2021

Zydus applies to the DCGI for EUA to launch ZyCoV-D

ZyCoV-D had already exhibited a robust immunogenicity and tolerability and safety profile in the adaptive Phase I/II clinical trials